Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ValiRxLSE:VAL Days Sales Outstanding is 382.66 as of Dec. 2025, which is 4% below its 10-year median of 400.56. The stock has 4 warning signs investors should review. Among 841 Biotechnology companies, ValiRx ranks worse than 96.31% on this metric.
ValiRx's average Accounts Receivable for the
six
months ended in Dec. 2025 was £0.07 Mil. ValiRx's Revenue for the
six
months ended in Dec. 2025 was £0.03 Mil.
Hence, ValiRx's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 382.66.
The historical rank and industry rank for ValiRx's Days Sales Outstanding or its related term are showing as below:
LSE:VAL'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 306.6 Med: 400.56 Max: 808.49
Current: 808.49
During the past 13 years, ValiRx's highest Days Sales Outstanding was 808.49. The lowest was 306.60. And the median was 400.56.
LSE:VAL's Days Sales Outstanding is ranked worse than 96.31% of 841
companies
in the Biotechnology industry
Industry Median: 68.98
vs LSE:VAL: 808.49
ValiRx's Days Sales Outstanding
increased
from Dec. 2024 (257.33) to Dec. 2025 (382.66).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
ValiRx (LSE:VAL) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
ValiRx Days Sales Outstanding Related Terms
ValiRx Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for ValiRx's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:VAL vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, ValiRx's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ValiRx Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ValiRx's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where ValiRx's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 382.66 mean?
ValiRx (LSE:VAL) has a Days Sales Outstanding of 382.66 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on ValiRx and its competitors. This is near median its historical median of 400.56. Over the past decade, ValiRx's Days Sales Outstanding has ranged from 306.60 to 808.49. According to the industry distribution chart, ValiRx ranks #810 out of 841 companies in the Biotechnology industry, placing it in the top 96.3%.
Is ValiRx's Days Sales Outstanding too high?
ValiRx's current Days Sales Outstanding of 382.66 is near median its 10-year median of 400.56. Over the past 10 years, this metric has ranged from a low of 306.60 to a high of 808.49. The Biotechnology industry median Days Sales Outstanding is 68.98. ValiRx's value of 382.66 is 454.7% above this industry median. Based on the distribution chart, ValiRx ranks #810 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does ValiRx's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ValiRx ranks #810 out of 841 companies for Days Sales Outstanding. This places ValiRx in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. ValiRx's value of 382.66 is 454.7% above this benchmark. Historically, ValiRx's own Days Sales Outstanding has ranged from 306.60 to 808.49 over the past decade. While the company's 10-year median is 400.56 vs. the industry median of 68.98, ValiRx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ValiRx's current Days Sales Outstanding of 382.66 is 454.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on ValiRx and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ValiRx's current Days Sales Outstanding is 382.66, which is near median its own 10-year median of 400.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ValiRx stock overvalued right now?
ValiRx (LSE:VAL) has a current Days Sales Outstanding of 382.66. The current Days Sales Outstanding is 382.66, which is near median its 10-year median of 400.56 and 454.7% above the Biotechnology industry median of 68.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For ValiRx (LSE:VAL), the current Days Sales Outstanding is 382.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VAL has been successfully added to your 
